Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta

SIMPLE SUMMARY: To further improve the antitumor efficacy of GD2-directed immunotherapies against high-risk neuroblastoma (NB), we investigated, in the present work, a combinatorial immunotherapy, with the chimeric antibody (Ab) dinutuximab beta (DB) and the double immune checkpoint blockade of T-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Siebert, Nikolai, Zumpe, Maxi, Schwencke, Christian Heinrich, Biskupski, Simon, Troschke-Meurer, Sascha, Leopold, Justus, Zikoridse, Alexander, Lode, Holger N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340720/
https://www.ncbi.nlm.nih.gov/pubmed/37444427
http://dx.doi.org/10.3390/cancers15133317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340720/
https://www.ncbi.nlm.nih.gov/pubmed/37444427
http://dx.doi.org/10.3390/cancers15133317

Ejemplares similares